FDA Approves Emgality for Episodic Cluster Headache
One June 4, 2019 the FDA approved Emgality (galcanezumab-gnlm) for the treatment of episodic cluster headache in adults. Emgality is …
Migraine News
FDA Approves New Nasal Spray Medication for Migraine Treatment
On January 30th, 2019, the United States Food and Drug Administration (FDA) approved a nasal spray for the treatment of …
Emgality Users, We Want to Hear From You!
Have you been prescribed Emgality and/or taken your first dose? If so, we’d like to hear from you. Please enter …
Emgality Approved for Migraine Prevention—Lilly Says Free for Some Insured Patients
Eli Lilly and Company received approval from the U.S. Food and Drug Administration (FDA) to market Emgality™ (galcanezumab-gnlm) for migraine …
Ajovy Approved by FDA as Second CGRP Blocker for Migraine Prevention
Today, the U.S. Food and Drug Administration (FDA) approved Ajovy™ (fremanezumab-vfrm) for the prevention of migraine in adults. Ajovy is …
How’s Your Relationship with Your Doctor? Take our Survey!
Do you feel heard by your doctor? Do your questions get answered? We want to hear from you! We’re conducting …
Phase 3 Clinical Trials’ Data on Oral CGRP Presented at AHS
The American Headache Society (AHS) hosted its Annual Scientific Meeting this past week, which included several late-breaking presentations from Biohaven …
Oral CGRPs Phase 3 Clinical Trial Now Recruiting
Biohaven Pharmaceuticals announced on March 6, 2018 that patients may enroll in a Phase 3 clinical trial to evaluate the …
Aimovig Approved by FDA as First Calcitonin-Gene-Related Peptide (CGRP) Blocker for Migraine Prevention
The U.S. Food and Drug Administration (FDA) has approved Aimovig as the first calcitonin-gene-related peptide (CGRP) blocker for the preventive …
Take the Clinical Trial Patient Experience Survey!
Have you participated in a clinical trial? We want to hear more about your experience! We are conducting a short …
Out of My Head Documentary
At this year’s Headache on the Hill, migraine advocates had the opportunity to attend the premiere of the highly anticipated, …
New Look, Same Great Community!
You might notice a few changes in the way things look when you visit Migraine.com. Never fear! You still have …
Ajovy Users, We Want to Hear From You!
Have you been prescribed Ajovy and/or taken your first dose? If so, we’d like to hear from you. Please enter …
Patient Input on CGRP Needed by May 8th
It’s time to rally the troops! Those who live with migraine disease have a chance to make an impact on the …
The Migraine World Summit
2019 Update: The free virtual Migraine World Summit is taking place March 20-28, 2019. Registration is required. Book your spot …
Headache on the Hill 2018 – How You Can Get Involved Now
On February 12 and 13, 2018, the Alliance for Headache Disorders Advocacy (AHDA) held its annual Headache on the Hill …
FDA Announces OTC Migraine Medications Will Now Include New Warning Label
In February 2015, a group of physicians, led by Dr. Jonathan H. Smith of the Department of Neurology at the …
Non-invasive Vagus Nerve Stimulator Approved to Treat Migraine Pain
On January 29, 2018, the FDA approved gammaCORE, a hand-held, non-invasive, vagus nerve stimulator (nVNS) for the treatment of migraine …
FDA Accepts BLA for Migraine Treatment, Grants Fast Track Designation for Development Program
This month, Teva Pharmaceutical Industries Ltd. announced that the U.S. FDA (Food and Drug Administration) has accepted for review the …
Patient Voices Needed for CGRP Insurance Coverage
Patients with migraine disease are being asked to share their stories for considerartion during a review of a new CGRP …